Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)

BACKGROUND: This phase I, open-label, first-in-human study determined dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of PD 0332991, an oral cyclin-dependent kinase 4/6 inhibitor with potent anti-proliferative activity in vitro/vivo. METHODS: A total of 33 patients with retinoblasto...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, G K, LoRusso, P M, Dickson, M A, Randolph, S S, Shaik, M N, Wilner, K D, Courtney, R, O'Dwyer, P J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Translational Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111206/
https://www.ncbi.nlm.nih.gov/pubmed/21610706
http://dx.doi.org/10.1038/bjc.2011.177

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3111206/
https://www.ncbi.nlm.nih.gov/pubmed/21610706
http://dx.doi.org/10.1038/bjc.2011.177

Ejemplares similares